Kumar, Sonal
Mohanty, Arpan
Mantry, Parvez
Schwartz, Robert E.
Haff, Madeleine
Therapondos, George
Noureddin, Mazen
Dieterich, Douglas
Girgrah, Nigel
Cohn, Kristi
Savanth, Mohanish
Fuchs, Michael
Article History
Received: 8 February 2024
Accepted: 10 July 2024
First Online: 20 July 2024
Declarations
:
: The protocol was submitted to the WCG IRB and local review boards. The WCG IRB issued a statement of exemption under 45 CFR § 46.104(d)(1) because the research is conducted in established or commonly accepted educational settings and the research specifically involves normal educational practices that are not likely to adversely impact students’ opportunity to learn required educational content or the assessment of educators who provide instruction. As such, the requirement for consent to participate was waived (for reference: work order #1–1557082-1).
: Not applicable.
: Potential competing interests of the authors are disclosed as follows - SK reported receiving funding as a principal investigator for various clinical studies supported by Novo Nordisk, Inc., Gilead Sciences, Intercept Pharmaceuticals, CymaBay Therapeutics, Ipsen, Madrigal Pharmaceuticals; and as a speaker for events supported by Gilead Sciences, Ipsen, Novo Nordisk, Intercept Pharmaceuticals. AM reported receiving grant funding from Gilead Sciences and The Kinetix Group; and as a principal investigator for various studies supported by Novo Nordisk, Inc., Intercept Pharmaceuticals, and Inventiva Pharma; and for serving on an advisory board supported by Gilead Sciences. RS reported receiving compensation for serving on scientific advisory boards supported by Miromatrix Inc. and Lime Therapeutics; and a paid consultant and speaker for Alnylam Inc. GT reported receiving compensation as a participant in multiple advisory boards supported by Novo Nordisk. MN reported receiving compensation as a participant on advisory boards supported by Altimmune, Boehringer Ingelheim, CytoDyn, Corcept Therapeutics, 89BIO Inc, GSK, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Inc., NorthSea Therapeutics, Terns Pharmaceuticals, and Takeda Pharmaceuticals; and as a principal investigator for studies supported by Allergan, Akero Therapeutics, BMS, Gilead Sciences, Galectin Therapeutics, Genfit, GSK, Conatus, Corcept Therapeutics, Enanta Pharmaceuticals, Madrigal Pharmaceuticals, Novartis, Novo Nordisk, Inc., Shire, Takeda Pharmaceuticals, Terns Pharmaceuticals, Viking, and Zydus; and reported being a stockholder in Rivus Pharma, CIMA, CytoDyn, and ChronWell, Inc. DD reported receiving compensation as a consultant for Novo Nordisk, Inc.; and as a speaker for events supported by Intercept Pharmaceuticals. NG reported receiving compensation as a participant of the speakers bureau supported by Gilead Sciences. KC and MS reported being employed by NASHNET/The Kinetix Group. No other disclosures were reported.